MRK vs RARE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
RARE exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative shareholders' equity (Price/Book of -29.89) and extreme profitability deficits, with a profit margin of -85.44%. While revenue growth remains positive at 25.9% and analysts maintain a 'strong_buy' rating based on pipeline potential, the deterministic data reveals a company with consistent earnings misses and a prohibitive Forward P/E of 306.64. The divergence between analyst optimism and the actual financial decay, coupled with bearish insider selling, suggests a high-risk profile.
Compare Another Pair
Related Comparisons
MRK vs RARE: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Ultragenyx Pharmaceutical Inc. (RARE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.